- Due to the progress in medicinal biology, over a hundred protein and peptide drugs, including: insulin, LHRH, somatostatin, gamma-globulin, monoclonal antibodies, and vaccines, have been used for treating various diseases.
- The advancement in the synthesis of recombinant peptides, proteins, DNA and RNA, as well as the exquisite specificity and reduced side effects inherent in their use has raised interest in their clinical development. Proteins and peptides present multiple benefits as potential drugs, such as: high selectivity, high potency, low toxicity, and low accumulation in tissue. However, due to large size, low stability, enzymatic degradation, and poor permeability through biological membranes, getting appropriate absorption and high bioavailability whether by oral or mucosal routes of administration is still a challenge.
- A delivery system for proteins and peptides to substitute the current standard which requires frequent injections.
- Our delivery system consists of copolymer of a GRAS approved polymer and insulin for sustained release of insulin.
Insulin nanoparticles made from the above copolymer were fully characterized and showed:
- In vitro and in vivo continuous release for 16 weeks, avoiding the need for multiple injections.
- High stability of the nanoparticles, that could be used for almost any peptide drug candidate.
We are seeking collaboration with drug delivery companies, and especially in the extended release of peptides and proteins.
Besides, the new biomaterials and scaffolds developed could be used for medical purposes but also for the cultured meat industry.